First In-human Study Update: Study Open for Enrolment

Dec 15, 2020
Posted in: News, Investor updates

Home » First In-human Study Update: Study Open for Enrolment

First In-human Study Update: Study Open for Enrolment

Dec 15, 2020
Posted in: News, Investor updates

Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense^® HER2 breast cancer Phase I first-in-human study.

Read the announcement.

Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting

May 25, 2023

Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session

2023 AGM Resolution Overview

May 11, 2023

Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting

Imagion initiates leadership restructuring plan

April 28, 2023

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

First In-human Study Update: Study Open for Enrolment

First In-human Study Update: Study Open for Enrolment

Related Articles

Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting

2023 AGM Resolution Overview

Imagion initiates leadership restructuring plan

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list